Related references
Note: Only part of the references are listed.Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
Tatsuo Kimura et al.
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2011)
Irinotecan therapy and molecular targets in colorectal cancer: A systemic review
Jessica Weekes et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer
Denis C. Talbot et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study of E7070 in patients with metastatic melanoma
JF Smyth et al.
ANNALS OF ONCOLOGY (2005)
Interaction between glucose-regulated destruction domain of DNA topoisomerase IIα and MPN domain of Jab1/CSN5
JS Yun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A phase II clinical and pharmacodynamic study of e7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: Modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor
RI Haddad et al.
CLINICAL CANCER RESEARCH (2004)
Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours.: A study by the EORTC Early Clinical Study Group (ECSG)
C Terret et al.
EUROPEAN JOURNAL OF CANCER (2003)
Quantitative chemical proteomics for identifying candidate drug targets
Y Oda et al.
ANALYTICAL CHEMISTRY (2003)
Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents
T Owa et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo
Y Ozawa et al.
EUROPEAN JOURNAL OF CANCER (2001)
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis
Y Kano et al.
LEUKEMIA (2000)
Share Paper
